Alan FRS - Tango Therapeutics Founder Board

TNGX Stock  USD 3.10  0.16  5.44%   

Insider

Alan FRS is Founder Board of Tango Therapeutics
Age 63
Phone857 320 4900
Webhttps://www.tangotx.com

Tango Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2237) % which means that it has lost $0.2237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4879) %, meaning that it created substantial loss on money invested by shareholders. Tango Therapeutics' management efficiency ratios could be used to measure how well Tango Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Tango Therapeutics currently holds 38.92 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Tango Therapeutics has a current ratio of 9.56, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Tango Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Daniel BensenTyra Biosciences
48
Thomas CatinazzoRelay Therapeutics
48
MD FACPRallybio Corp
73
MD MBAShattuck Labs
65
Desiree DDSPassage Bio
N/A
MBA MDPliant Therapeutics
56
Stefani WolffNurix Therapeutics
62
William HoRAPT Therapeutics
58
Gwenn HansenNurix Therapeutics
53
Sergey MDBlack Diamond Therapeutics
55
Andy PorterRelay Therapeutics
N/A
BCPS PharmDXilio Development
47
Kerry WhalenCullinan Oncology LLC
N/A
Lei SunConnect Biopharma Holdings
60
Jared MDKymera Therapeutics
59
Melissa BrodyKymera Therapeutics
N/A
Christopher RobertsBlack Diamond Therapeutics
54
Nello MDKymera Therapeutics
45
Jack AndersRevolution Medicines
48
Alan RussellEdgewise Therapeutics
54
Ami BavishiRallybio Corp
N/A
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts. Tango Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 103 people. Tango Therapeutics (TNGX) is traded on NASDAQ Exchange in USA. It is located in 201 Brookline Avenue, Boston, MA, United States, 02215 and employs 140 people. Tango Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Tango Therapeutics Leadership Team

Elected by the shareholders, the Tango Therapeutics' board of directors comprises two types of representatives: Tango Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tango. The board's role is to monitor Tango Therapeutics' management team and ensure that shareholders' interests are well served. Tango Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tango Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
MD Kaelin, Founder Board
Antoni MD, Founder Board
Barbara MD, CEO President
Daniella CPA, Chief Officer
Alan Huang, Chief Officer
Levi MD, Founder
JD Esq, Chief Counsel
Heather MS, Chief Officer
Alan FRS, Founder Board
Michael Palmieri, Manufacturing, Chemistry
Jannik Andersen, Chief Officer
John MS, Vice Resources
Charles Davis, Senior Pharmacology
Timothy Redfern, Chief Officer

Tango Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tango Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.